May 16 2012
Covidien
(NYSE: COV), a leading global provider of healthcare products, today
announced that it has completed the previously announced acquisition of
superDimension, Ltd., for an aggregate consideration of approximately
$300 million, with future earn out payments possible.
Pursuant to the terms of the acquisition agreement, Covidien has
acquired all of the outstanding capital stock of superDimension, a
private company based in Herzliya, Israel, that develops minimally
invasive interventional pulmonology devices.
"Covidien's strategy is to invest in relevant products and technologies
which can meaningfully improve patient outcomes while reducing the
overall cost of care," said Bryan Hanson, Group President, Surgical
Solutions, Covidien. "The acquisition of superDimension positions
Covidien to continue its investment in meaningful innovation by
delivering more comprehensive solutions in the evaluation and management
of lung diseases."
Study reveals AI's potential and pitfalls in medical diagnosis